Shares of Trevi Therapeutics Inc. jumped 38.1% in premarket trading on Wednesday after the company said its experimental treatment for prurigo nodularis, a type of inflammatory skin disease, met the primary endpoint in a Phase 2b/3 clinical trial. If approved, the oral treatment would be the first therapy to treat prurigo nodularis, Trevi said. The company’s stock has soared 158.2% this year, while the broader S&P 500 is down 19.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.